Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Eli Lilly stock has delivered a 406.3% return over the past five years, yet its latest valuation checks point to an unusual tension as the Discounted Cash Flow (DCF) intrinsic value suggests the shares trade at a discount while the broader scorecard still leans expensive.
A roughly 5x gain over five years can signal that a lot of optimism is already reflected in Eli Lilly’s share price, putting more focus on what investors are paying for that growth story today.
Expectations tied to obesity, diabetes and neuroscience pipelines may support the long term cash flow outlook, but regulatory and pricing pressures highlighted in recent coverage can weigh on how much of that potential is ultimately realized in shareholder value.
With Eli Lilly scoring just 2 out of 6 on our valuation checks, the stock does not screen as a clear bargain even though the DCF estimate points to it being around 28.3% below intrinsic value.
For investors, the debate is whether Eli Lilly’s recent share price levels leave enough margin of safety if the intrinsic value estimate is right, or whether the low score on the broader checks is a warning that expectations have run ahead of fundamentals.
The Discounted Cash Flow (DCF) approach estimates what Eli Lilly is worth today based on the cash it is expected to generate in the future. Eli Lilly’s latest twelve month free cash flow sits at about $8.6b, and the model assumes that these cash flows continue growing over time rather than shrinking or merely holding flat.
On those assumptions, the DCF model arrives at an intrinsic value of about $1,644 per share, which sits roughly 28.3% above the current share price and indicates that Eli Lilly stock is trading at a discount to its cash flow estimate. The recent surge in demand for GLP 1 treatments and expanded use of drugs like Mounjaro and Zepbound is presented as a factor that may help explain why the market is still pricing Eli Lilly below what this cash flow model suggests.
Overall, the DCF view is that Eli Lilly currently appears undervalued relative to its estimated intrinsic value.
P/E is a useful lens for Eli Lilly because earnings are a key focus for how investors are currently framing its obesity, diabetes and neuroscience franchises. Eli Lilly trades on a P/E of about 41.6x, well above the Pharmaceuticals industry average of 15.0x and also above a peer average of 25.1x, which shows investors are willing to pay a clear premium for each dollar of current earnings.
The fair P/E ratio from the model sits at 39.2x, only slightly below the current 41.6x level. This suggests that while Eli Lilly screens expensive against broad sector benchmarks, it looks closer to balanced once its growth profile, margins, scale and risks are factored in. In other words, the stock no longer looks cheap against its own earnings power, but it also does not screen as wildly stretched relative to this tailored fair multiple.
On the P/E multiple, Eli Lilly looks roughly fairly valued once you account for its business profile and risk trade offs.
The Eli Lilly Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives for Eli Lilly pick up where this valuation puzzle leaves off by spelling out which assumptions about Eli Lilly’s future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today’s price. Each Narrative sets out a fair value as a thesis about how the business develops over time, so you can track how that view holds up, and they sit on Simply Wall St’s Community page.
Eli Lilly investors in the community are split between a long runway for GLP 1 demand and concern that pricing power and concentration risks are already reflected in the stock.
Bull case: roughly fairly valued
“Market penetration for all GLP-1 drugs is only at 4% of target audience of 100 to 120 million people in the USA alone…”
“The likelihood of significant drug pricing reforms in the U.S., combined with initiatives to increase pricing parity between the U.S. and Europe, threatens to sharply limit Eli Lilly’s future pricing power…”
For Eli Lilly, the Discounted Cash Flow (DCF) intrinsic value points to an undervalued stock, while the P/E based view suggests pricing that is roughly in line with its earnings profile. That split reflects how cash flow models lean on long term obesity and diabetes demand, while the market multiple embeds already high expectations after a sharp share price move. The broader valuation checks still look weak, so the key question is whether Eli Lilly can sustain the growth and pricing power implied by those cash flow assumptions without regulatory or competitive setbacks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
